CelLBxHealth plc (LSE:CLBX) has entered into a Master Services Agreement with AstraZeneca that establishes the company as an approved provider of circulating tumour cell (CTC)-based analytical services for clinical trial programmes.
Under the agreement, CelLBxHealth will be able to support AstraZeneca’s research and development activities using its proprietary Parsortix platform, which is designed to isolate and analyse circulating tumour cells from blood samples. The framework agreement provides the potential for the company to contribute analytical services across multiple programmes within AstraZeneca’s clinical development pipeline.
Management believes the arrangement represents an important commercial milestone, expanding the company’s reach within the pharmaceutical sector and reinforcing the value of its CTC technology in drug development and clinical research applications. The agreement also strengthens CelLBxHealth’s position as a specialist provider of advanced cancer analytics services to major biopharmaceutical companies.
The Parsortix platform enables the capture of rare circulating tumour cells from blood samples, allowing researchers to conduct detailed molecular, genomic and proteomic analyses. Such capabilities can provide valuable insights into cancer biology, treatment response and disease progression, supporting both drug development and precision medicine initiatives.
The new relationship with AstraZeneca is expected to enhance CelLBxHealth’s visibility within the pharmaceutical industry and create opportunities for additional service contracts as demand for advanced biomarker analysis and liquid biopsy technologies continues to grow.
More about CelLBxHealth plc
CelLBxHealth plc is a biotechnology company specialising in circulating tumour cell intelligence and cancer-related diagnostic technologies. The company’s patented Parsortix platform is designed to harvest circulating tumour cells from blood samples, enabling advanced analysis for oncology research, drug development and potential clinical applications.
Its business model combines product sales, laboratory services, clinical trial support and the development of laboratory-developed tests. By integrating CTC analysis with imaging, genomic and proteomic technologies, CelLBxHealth aims to provide valuable insights for pharmaceutical companies, researchers and healthcare providers working to improve cancer diagnosis and treatment.
Leave a Reply